Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Cancer Research UK Randomised, Double Blind, Placebo Controlled Phase IIa Trial of AMG 319 Given Orally as a Neoadjuvant Therapy in Patients With Human Papillomavirus (HPV) Positive and Negative Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT02540928 is registered in ClinicalTrials.gov with Cancer Research UK as lead sponsor.

NCT NCT02540928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02540928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Cancer Research UK Randomised, Double Blind, Placebo Controlled Phase IIa Trial of AMG 319 Given Orally as a Neoadjuvant Therapy in Patients With Human Papillomavirus (HPV) Positive and Negative Head and Neck Squamous Cell Carcinoma (HNSCC)
Lead sponsor
Cancer Research UK
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2015
Completion date
May 3, 2018
Enrollment
35 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

human papillomavirus (hpv), positive or negative head and neck squamous cell carcinoma (hnscc) of the hypopharynx, oropharynx, oral cavity, supraglottis or larynx